Prostate cancer has long been a nightmare for immunotherapy doctors. Unlike some tumors that light up like beacons to the immune system, prostate cancers are what researchers call "immune cold" - they repel the very T cells needed to attack them. Now scientists have found a way to flip that switch, potentially transforming how this disease is treated.
A team led by researchers at Duke University School of Medicine developed an experimental CRISPR tool that forces cancer cells to display a molecular signal that immune cells recognize and attack. In laboratory tests with mice, tumors treated with this new approach became dramatically more vulnerable to standard immunotherapy drugs. The work appears in Nature Biomedical Engineering.
"Immune therapy is a monumentally different way to treat cancer, and a great way because you don't have to give patients terrible drugs that kill the cancer but harm healthy cells in the process," said Eric J. Wagner, a biochemistry professor at the University of Rochester Medicine and co-author of the study. "The problem is that some cancers respond well to immune therapy, but others develop resistance or don't respond at all."
The discovery traces back over a decade. Wagner's team was studying glioblastoma when they noticed tumor cells were making abnormally shortened versions of messenger RNA, the genetic instructions cells use to build proteins. That shortening turned out to be a survival trick cancer uses across many types of tumors.
Shorter RNA molecules are tougher for the cell to break down, giving them more time to keep producing the proteins they encode. It's like cancer cells are using a compression technique to hide themselves better from normal cellular cleanup.
In prostate cancer specifically, this shortening strategy sabotages immune recognition. Cancer cells make extra copies of a protein called SPSB1, which destroys the MHC-1 complex. Think of MHC-1 as a neon sign that tells T cells "tumor here." Without it, immune cells walk right past the cancer cells without recognizing them as enemies.
The researchers identified the exact culprit. The mRNA instructions for making SPSB1 were being shortened, leading cancer cells to pump out excessive amounts of the protein. More SPSB1 meant less MHC-1 on tumor cell surfaces, making the cancer invisible to immunotherapy.
Wagner's team engineered a CRISPR-Cas13 system to reverse the process. Unlike traditional CRISPR tools that cut DNA or RNA, this system was designed to bind to a specific spot on the shortened SPSB1 mRNA and prevent the cancer cell from chopping off its tail. By keeping the RNA at its natural, longer length, the cancer cells produced much less SPSB1 protein.
With less SPSB1 being made, the MHC-1 complex returned to the tumor cell surface. Once that molecular signal was restored, immune checkpoint inhibitors - existing drugs that remove the brakes on T cells - became far more effective. Immune cells flooded into the tumors and destroyed cancer cells.
"Cancer is super smart at evolving, but it's not a magician," Wagner said. "If we can hit it with immunotherapy and another synergistic drug that pumps up the immune response, we could potentially cure it. It won't be able to evolve fast enough."
The preclinical findings showed no detectable off-target effects from the CRISPR treatment, a critical safety consideration for any potential therapy. Wagner's team is now testing whether the same approach works against other immune-cold tumors, starting with pancreatic cancer, another malignancy that typically resists immunotherapy.
Author Jessica Williams: "This is the kind of creative hit that could crack open a major clinical problem, but the gap between mice and patients is still real wide - let's see if it holds up in actual human trials."
Comments